A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg assay panel and the B-Cell/antibody response panel to predict the clinical effect of Octagam 5% in subjects with relapsing/remitting multiple sclerosis.

Trial Profile

A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg assay panel and the B-Cell/antibody response panel to predict the clinical effect of Octagam 5% in subjects with relapsing/remitting multiple sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2013

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Octapharma
  • Most Recent Events

    • 20 Sep 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 26 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top